What is Mercy Bioanalytics?
Mercy Bioanalytics, Inc. is a pioneering biotechnology enterprise dedicated to the early identification of cancer, specifically targeting difficult-to-treat conditions such as ovarian and lung cancer. The company utilizes extracellular vesicles (EVs)—abundant nanoparticles that carry vital biological information from parent cells—to detect malignancies at stages where clinical intervention is most effective. By transforming how clinicians approach diagnostic screening, Mercy Bioanalytics aims to shift the paradigm from reactive treatment to proactive, life-saving detection. Their market position is bolstered by a sophisticated R&D pipeline and a growing network of strategic partners in the life sciences and medical technology sectors.
How much funding has Mercy Bioanalytics raised?
Mercy Bioanalytics has raised a total of $100M across 2 funding rounds:
Series A
$41M
Series B
$59M
Series A (2023): $41M with participation from Hatteras Venture Partners, iSelect Fund Management, Sozo Ventures, and Novalis LifeSciences
Series B (2025): $59M led by Bruker Scientific, Avestria Ventures Management, BrightEdge - American Cancer Society, Novalis Trust, iSelect Fund Management, Xontogeny, Portfolia, Hologic, Sozo Ventures, and Labcorp
Key Investors in Mercy Bioanalytics
BrightEdge - American Cancer Society
The innovation and impact investment arm of the American Cancer Society, focusing on scalable solutions that address critical unmet needs in cancer care.
Labcorp
A global laboratory services leader providing comprehensive diagnostic and biopharma laboratory services to support confident clinical decision-making.
Hologic
A medical technology company specializing in women's health, providing advanced diagnostic products, imaging systems, and surgical tools.
What's next for Mercy Bioanalytics?
With the recent influx of capital, Mercy Bioanalytics is well-positioned to accelerate its clinical proof-of-concept studies and expand its diagnostic platform. The company's strategic roadmap focuses on scaling its proprietary EV-based detection methods to meet the rigorous demands of global healthcare systems. As it transitions from development to broader clinical application, the firm will likely prioritize partnerships with established diagnostic leaders to integrate its technology into standard oncology workflows. This phase of growth is expected to solidify its status as a category leader in the precision medicine landscape, ultimately aiming to reduce mortality rates through earlier, more accurate diagnostic insights.
See full Mercy Bioanalytics company page
